IP Library Granted Patent US 7,271,239
Granted Patent B2
US 7,271,239 · App. 11/213,245 · Granted Sep 18, 2007

D-isomers of antimicrobial peptide

Assignee: The Research Foundation of State University of New York
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,271,239
App. No.
11/213,245
Granted
Sep 18, 2007
Kind
B2
Abstract

This invention provides D-isomers of MUC7-12-mer peptide of human saliva MUC7. The isomers have antimicrobial activity comparable to that of the L-isomers and are resistant to proteolysis. These peptides can be used as antifungal and antimicrobial agents.

Claims (14)

1. An isolated and purified peptide of SEQ ID NO:1, wherein all of the amino acids are D amino acids.

2. A method of killing bacteria or fungi comprising the steps of exposing the bacterial or fungal cells to a bactericidal or fungicidal composition comprising the peptide of claim 1 .

3. The method of claim 2 , wherein the bacteria are selected from the group consisting of, Escherichia coli, Streptoccocus gordonii, Streptococcus mutans, Actinobacillus actinomycetemcimitans and Pseudomonas gingivalis.

4. The method of claim 2 , wherein the bacteria are present in a biofilm.

5. The method of claim 4 , wherein the biofilm is present in the oral cavity.

6. The method of claim 5 , wherein the bacteria in the biofilm comprise S. mutans.

7. The method of claim 2 , wherein the fungi are selected from the group consisting of Candida albicans, Candida glabrata, Crytococus neoformans, Candida krusei and Saccharomyces cerevisiae.

8. The method of claim 2 , wherein the peptide is used at a concentration of 25 to 200 μM.

9. The method of claim 8 , wherein the peptide is used at a concentration of about 100 μM.

10. The method of claim 9 , wherein the peptide is used with EDTA at a concentration of about 1 mM.

11. An oral composition comprising the peptide of claim 1 .

12. The oral composition of claim 11 further comprising ethylenediaminetratra acetic acid (EDTA).

13. The oral composition of claim 12 , wherein the EDTA is present at a concentration of between 0.5 to 2.0 mM.

14. The oral composition of claim 13 , wherein the EDTA is present at a concentration of about 1 mM.

Assignments (4)
CONFIRMATORY LICENSE Recorded Jan 11, 2024
From: RESEARCH FOUNDATION OF STATE UNIVERSITY OF NY, UNIVERSITY AT BUFFALO
To: NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR
Reel/Frame 066092/0124 →
CONFIRMATORY LICENSE Recorded Jan 10, 2024
From: RESEARCH FOUNDATION OF STATE UNIVERSITY OF NY, UNIVERSITY AT BUFFALO
To: NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR
Reel/Frame 066076/0889 →
EXECUTIVE ORDER 9424, CONFIRMATORY LICENSE Recorded Oct 27, 2008
From: STATE UNIVERSITY OF NEW YORK AT BUFFALO
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 021743/0638 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 16, 2005
From: BOBEK, LIBUSE A.
To: RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK AT BUFFALO, THE
Reel/Frame 017360/0530 →
Continuity (2)
Provisional Application 6060631200 · Sep 1, 2004
Related Publication 20060069022A1 · Mar 30, 2006